Cargando…

Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma

BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups....

Descripción completa

Detalles Bibliográficos
Autores principales: Lamm, Wolfgang, Natter, Camilla, Schur, Sophie, Köstler, Wolfgang J, Reinthaller, Alexander, Krainer, Michael, Grimm, Christoph, Horvath, Reinhard, Amann, Gabriele, Funovics, Philipp, Brodowicz, Thomas, Polterauer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320583/
https://www.ncbi.nlm.nih.gov/pubmed/25523155
http://dx.doi.org/10.1186/1471-2407-14-981
_version_ 1782356147139772416
author Lamm, Wolfgang
Natter, Camilla
Schur, Sophie
Köstler, Wolfgang J
Reinthaller, Alexander
Krainer, Michael
Grimm, Christoph
Horvath, Reinhard
Amann, Gabriele
Funovics, Philipp
Brodowicz, Thomas
Polterauer, Stephan
author_facet Lamm, Wolfgang
Natter, Camilla
Schur, Sophie
Köstler, Wolfgang J
Reinthaller, Alexander
Krainer, Michael
Grimm, Christoph
Horvath, Reinhard
Amann, Gabriele
Funovics, Philipp
Brodowicz, Thomas
Polterauer, Stephan
author_sort Lamm, Wolfgang
collection PubMed
description BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. METHODS: Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. RESULTS: Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS, respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in terms of OS (p < 0.0001). CONCLUSION: At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological tumor behavior.
format Online
Article
Text
id pubmed-4320583
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43205832015-02-08 Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma Lamm, Wolfgang Natter, Camilla Schur, Sophie Köstler, Wolfgang J Reinthaller, Alexander Krainer, Michael Grimm, Christoph Horvath, Reinhard Amann, Gabriele Funovics, Philipp Brodowicz, Thomas Polterauer, Stephan BMC Cancer Research Article BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. METHODS: Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. RESULTS: Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS, respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in terms of OS (p < 0.0001). CONCLUSION: At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological tumor behavior. BioMed Central 2014-12-18 /pmc/articles/PMC4320583/ /pubmed/25523155 http://dx.doi.org/10.1186/1471-2407-14-981 Text en © Lamm et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lamm, Wolfgang
Natter, Camilla
Schur, Sophie
Köstler, Wolfgang J
Reinthaller, Alexander
Krainer, Michael
Grimm, Christoph
Horvath, Reinhard
Amann, Gabriele
Funovics, Philipp
Brodowicz, Thomas
Polterauer, Stephan
Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title_full Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title_fullStr Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title_full_unstemmed Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title_short Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
title_sort distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320583/
https://www.ncbi.nlm.nih.gov/pubmed/25523155
http://dx.doi.org/10.1186/1471-2407-14-981
work_keys_str_mv AT lammwolfgang distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT nattercamilla distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT schursophie distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT kostlerwolfgangj distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT reinthalleralexander distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT krainermichael distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT grimmchristoph distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT horvathreinhard distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT amanngabriele distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT funovicsphilipp distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT brodowiczthomas distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma
AT polterauerstephan distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma